Text

Description automatically generated with medium confidence

**ASCO Meeting 2024 Participation**

**2024 Young Investigator Award Recipients**

Talal El Zarif, MD

Rebecca Forman, MD

Yiduo Hu, MD, PhD

Ritu Jayakrishnan, MD

Tendai Kwaramba, MD, MSc

Alejandro Rios-Hoyo, MD

**ASCO Education Scholar**

Thejal Srikumar, MD

**Friday, May 31**

*Workshop*

In-Person Workshop: Genomics 101 for Oncologists

[Medical Oncologist Perspective](https://meetings.asco.org/2024-asco-annual-meeting/15849?presentation=230887#230887)

May 31; 1:00 – 5:00 PM CDT

Presenter: Michael E. Hurwitz, MD, PhD

Location: S105ab

**Saturday, June 1**

*Oral Abstract*

Genitourinary Cancer—Kidney and Bladder

[Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).](https://meetings.asco.org/abstracts-presentations/234411)

June 1; 8:42 – 8:48AM CDT

Presenter: Soki Kashima

Senior Author: David Braun

Location: S100bc | Abstract 4515

*Poster Session*

Developmental Therapeutics—Immunotherapy

[SH2B3 mutation as a potential resistance mechanism to oncolytic virus therapy.](https://meetings.asco.org/abstracts-presentations/233950)

June 1; 9:00 – 12:00PM CDT

Presenter: Philippos Costa

Location: Hall A | Abstract 2578 | Poster Bd 57

*Poster Session*

Developmental Therapeutics—Immunotherapy

[Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.](https://meetings.asco.org/abstracts-presentations/234004)

June 1; 9:00 – 12:00PM CDT

Presenter: Alexander Frey

Senior Author: Jeffrey Ishizuka

Location: Hall A | Abstract 2637 | Poster Bd 116

Poster Session

Developmental Therapeutics—Immunotherapy

[A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.](https://meetings.asco.org/2024-asco-annual-meeting/15821?presentation=238326#238326)

June 1; 9:00 – 12:00PM CDT

Senior Author: Barbara Burtness

Location: Hall A | Abstract TPS2701 | Poster Bd 164a

*Poster Session*

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

[Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA)](https://meetings.asco.org/2024%20ASCO%20Annual%20Meeting/15824?presentation=234052#234052) [therapy: Safety and efficacy findings.](https://meetings.asco.org/2024%20ASCO%20Annual%20Meeting/15824?presentation=234052#234052)

June 1; 9:00 – 12:00PM CDT

Author: Pamela Kunz

Location: Hall A | Abstract 3091 | Poster Bd 236

*Poster Session*

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

[Comprehensive characterization of ERBB2 genomic alterations in lung cancer.](https://meetings.asco.org/abstracts-presentations/234147)

June 1; 9:00 – 12:00PM CDT

Presenter: Talal El Zarif

Location: Hall A | Abstract 3148 | Poster Bd 293

*Poster Session*

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

[HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.](https://meetings.asco.org/abstracts-presentations/238354)

June 1; 9:00 – 12:00PM CDT

Presenter: Aarti Bhatia

Location: Hall A | Abstract TPS3164 | Poster Bd 307a

*Poster Session*

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

[A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer.](https://meetings.asco.org/2024-asco-annual-meeting/15824?presentation=238355#238355)

June 1; 9:00 – 12:00 PM CDT

Senior Author: Patricia LoRusso

Location: Hall A | Abstract TPS3183 | Poster Bd 316a

*Poster Session*

Central Nervous System Tumors

[Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.](https://meetings.asco.org/abstracts-presentations/233831)

Presenter: Nicholas Blondin

June 1; 9:00 – 12:00PM CDT

Location: Hall A | Abstract: 2029 | Poster Bd 328

*Education Session*

Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates

[Role of Payload and Antibody in Predicting Resistance to Antibody-Drug Conjugates](https://meetings.asco.org/2024-asco-annual-meeting/15727?presentation=228499#228499)

June 1; 1:15 – 1:30PM CDT

Presenter: Patricia LoRusso

Location: Hall D1

*Education Session*

Tackling the Tough Stuff: Managing Challenging Symptoms and Patient Conversations Around Goals of Care

[Primary Palliative Care Skills: How to Integrate Into Your Oncology Practice](https://meetings.asco.org/abstracts-presentations/230501)

June 1; 1:15 – 1:30PM CDT

Presenter: Jennifer Kapo

Location: E450a

*Education Session*

State-of-the-Art Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma: Current Advances and Future Frontiers

[Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches](https://meetings.asco.org/2024-asco-annual-meeting/15711?presentation=228446#228446)

June 1; 1:30 – 1:45 PM CDT

Presenter: David Braun

Location: Hall D2

*Poster Session*

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

[Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.](https://meetings.asco.org/abstracts-presentations/234339)

June 1; 1:30 – 4:30PM CDT

Presenter: Pamela Kunz

Location: Hall A | Abstract 4131 | Poster Bd 111

*Poster Session*

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

[Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).](https://meetings.asco.org/abstracts-presentations/234244)

June 1; 1:30 – 4:30PM CDT

Presenter: Jacquelyne Gaddy

Location: Hall A | Abstract 4138 | Poster Bd 118

*Poster Session*

Melanoma/Skin Cancers

[Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials.](https://meetings.asco.org/abstracts-presentations/239182)

June 1; 1:30 – 4:30PM CDT

Presenter: Thazin Aung

Location: Hall A | Abstract 9567 | Poster Bd 351

*Poster Session*

Sarcoma

[Sorafenib treatment duration in desmoid tumors.](https://meetings.asco.org/abstracts-presentations/233375)

June 1; 1:30 – 4:30PM CDT

Presenter: Philippos Costa

Location: Hall A | Abstract 11585 | Poster Bd 511

*Education Session*

Advanced Lung Cancer: State-of-the-Art Approaches and Insights

[Small Cell Lung Cancer](https://meetings.asco.org/abstracts-presentations/228373)

June 1; 3:00 – 3:15 PM CDT

Presenter: Anne C. Chiang

Location: S406

*Oral Abstract*

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

[A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.](https://meetings.asco.org/abstracts-presentations/238945)

June 1; 4:24 – 4:36PM CDT

Presenter: Pat LoRusso

Location: Hall D1 | Abstract 3006 |

*Education Session*

[Navigating the Complexities of Brain Metastases Management](https://meetings.asco.org/2024-asco-annual-meeting/15689?presentation=228384#228384)

June 1; 4:45 -6:00 PM CDT

Chair: Sarah B. Goldberg, MD

Location: E450a

*Education Session*

[Has the Revolution in Precision Medicine Reached Patients With Brain Metastases?](https://meetings.asco.org/abstracts-presentations/228384)

June 1; 4:45 -5:00 PM CDT

Presenter: Sarah B. Goldberg, MD

Location: E450a

**Sunday, June 2**

*Oral Abstract*

Gastrointestinal Cancer—Colorectal and Anal

[ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).](https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231642#231642)

June 2; 10:24 – 10:36 AM CDT

Senior Author: Michael Cecchini

Location: Arie Crown Theater | Abstract 3508

*Poster Session*

Breast Cancer

[Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.](https://meetings.asco.org/2024-asco-annual-meeting/15812?presentation=233608#233608)

June 2; 9:00 – 12:00PM CDT

Senior Author: Maryam Lustberg

Location: Hall A | Abstract 1065 | Poster Bd 43

*Poster Session*

Breast Cancer—Metastatic

[Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).](https://meetings.asco.org/abstracts-presentations/233551)

June 2; 9:00 – 12:00PM CDT

Presenter: Melissa Taylor

Location: Hall A | Abstract 1092 | Poster Bd 70

*Poster Session*

Breast Cancer

[Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.](https://meetings.asco.org/abstracts-presentations/233556)

June 2; 9:00 – 12:00PM CDT

Presenter: Nicole Odzer

Location: Hall A | Abstract 1104 | Poster Bd 82

*Poster Session*

Breast Cancer—Local/Regional/Adjuvant

[Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer.](https://meetings.asco.org/abstracts-presentations/233442)

[article](https://meetings.asco.org/abstracts-presentations/233442)

June 2; 9:00 – 12:00PM CDT

Presenter: Daniel O'Neil

Location: Hall A| Abstract 522| Poster Bd 114

*Poster Session*

Breast Cancer—Local/Regional/Adjuvant

[Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.](https://meetings.asco.org/abstracts-presentations/233519)

June 2; 9:00 – 12:00PM CDT

Presenter: Alejandro Rios-Hoyo

Location: Hall A | Abstract 573 | Poster Bd 165

*Poster Session*

Genitourinary Cancer—Kidney and Bladder

[Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).](https://meetings.asco.org/2024-asco-annual-meeting/15833?presentation=231926#231926)

June 2; 9:00 – 12:00PM CDT

Senior Author: David Braun

Location: Hall A | Abstract 4546 | Poster Bd 241

*Poster Session*

Genitourinary Cancer—Kidney and Bladder

[A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.](https://meetings.asco.org/2024-asco-annual-meeting/15833?presentation=238443#238443)

June 2; 9:00 – 12:00PM CDT

Senior Author: Dan Petrylak

Location: Hall A | Abstract TPS4619 | Poster Bd 308a

*Poster Session*

Head and Neck Cancer

[Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study.](https://meetings.asco.org/2024-asco-annual-meeting/15842?presentation=234816#234816)

June 2; 9:00 – 12:00 PM CDT

Senior Author: Joseph Kim

Location: Hall A | Abstract 6079 | Poster Bd 395

*Case-Based Panel*

Optimizing Treatment of Locally Advanced Non–Small Cell Lung Cancer: A Multimodal Approach in the Immunotherapy Era

[Radiation Oncologist Perspective](https://meetings.asco.org/abstracts-presentations/228371)

June 2; 11:30 AM CDT

Presenter: Henry Soo-Min Park

Location: Hall D1

Clinical Science Symposium

Care Delivery and Quality Care

[Navigating Global Cancer Care: Conflict, Access, and Delivery](https://meetings.asco.org/2024-asco-annual-meeting/15861?presentation=232492#232492)

June 2; 12:18 – 12:30 PM CDT

Presenter: Daniel O’Neil

Location: S100bc

*Oral Abstract*

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

[Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).](https://meetings.asco.org/abstracts-presentations/232382)

June 2; 4:30 – 6:00PM CDT

Presenter: Ritujith Jayakrishnan

Location: S406 | Abstract 8013

**Monday, June 3**

*Oral Abstract*

Genitourinary Cancer—Kidney and Bladder

[Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.](https://meetings.asco.org/abstracts-presentations/234403)

June 3; 8:24 – 8:36AM CDT

Presenter: Daniel Petrylak

Location: Hall B1 | Abstract 4503

*Poster Session*

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

[Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.](https://meetings.asco.org/abstracts-presentations/232596)

June 3; 9:00 – 12:00PM CDT

Presenter: Amer Zeidan

Location: Hall A | Abstract 6565 | Poster Bd 124

*Poster Session*

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

[Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.](https://meetings.asco.org/abstracts-presentations/232598)

June 3; 9:00 – 12:00PM CDT

Presenter: Amer Zeidan

Location: Hall A | Abstract 6566| Poster Bd 125

*Poster Session*

Hematologic Malignancies—Plasma Cell Dyscrasia

[Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).](https://meetings.asco.org/abstracts-presentations/232774)

June 3; 9:00 – 12:00PM CDT

Presenter: Poy Theprungsirikul

Location: Hall A | Abstract 7549 | Poster Bd 186

*Poster Session*

Hematologic Malignancies—Plasma Cell Dyscrasia

[Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.](https://meetings.asco.org/abstracts-presentations/238727)

June 3; 9:00 – 12:00PM CDT

Presenter: Sabrina Browning

Location: Hall A | Abstract 7559 | Poster Bd 196

*Poster Session*

Quality Care/Health Services Research

[Opioid prescribing trends and pain scores among adult patients with cancer in a large health system](https://meetings.asco.org/abstracts-presentations/233194).

June 3; 9:00 – 12:00PM CDT  
Presenter: Laura Baum

Location: Hall A | Abstract 447678 | Poster Bd 254

*Poster Session*

Quality Care/Health Services Research

[Oral cancer drug repositories: Challenges and solutions.](https://meetings.asco.org/abstracts-presentations/233202)

June 3; 9:00 – 12:00PM CDT

Senior Author: Osama Abdelghany

Location: Hall A | Abstract 11063 | Poster Bd 258

*Poster Session*

Quality Care/Health Services Research

[Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.](https://meetings.asco.org/2024-asco-annual-meeting/15793?presentation=233281#233281)

June 3; 9:00 – 12:00PM CDT

Senior Author: Maureen Canavan

Location: Hall A | Abstract 11092 | Poster Bd 287

*Oral Abstract*

Medical Education and Professional Development

[Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.](https://meetings.asco.org/abstracts-presentations/231737)

Presenter: Thejal Srikumar

June 3; 9:51 – 9:57AM CDT

Location: E450a | Abstract 9004

*Oral Abstract*

Medical Education and Professional Development

[Evaluating speaker gender in scientific sessions at ASCO and ASCO GI (2019-2023)](https://meetings.asco.org/2024%20ASCO%20Annual%20Meeting/15782?presentation=232932#232932)

Author: Pamela Kunz

June 3; 10:45 – 10:51 AM CDT

Location: E450a| Abstract 9009

*Oral Abstract*

Genitourinary Cancer—Prostate, Testicular, and Penile

[ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.](https://meetings.asco.org/abstracts-presentations/234518)

June 3; 1:27 – 1:33PM CDT

Presenter: Daniel Petrylak

Location: Hall B1| Abstract 5011

*Poster Session*

Prevention, Risk Reduction, and Genetics

[Population attributable fraction of reproductive factors in triple negative breast cancer by race.](https://meetings.asco.org/abstracts-presentations/238748)

June 3; 1:30 – 4:30PM CDT

Presenter: Rachel Jaber Chehayeb

Location: Hall A | Abstract 10522| Poster Bd 49

*Poster Session*

Prevention, Risk Reduction, and Genetics

[Estimating risk for pancreatic cancer among 9.4 million veterans in care.](https://meetings.asco.org/abstracts-presentations/233118)

June 3; 1:30 – 4:30PM CDT

Presenter: Louise Wang

Location: Hall A | Abstract 10544 | Poster Bd 71

*Poster Session*

Prevention, Risk Reduction, and Genetics

[Blood type as a risk factor for pancreatic ductal adenocarcinoma.](https://meetings.asco.org/abstracts-presentations/233070)

June 3; 1:30 – 4:30PM CDT

Presenter: Navid Rahimi Larki

Location: Hall A | Abstract 10559 | Poster Bd 86

*Poster Session*

Prevention, Risk Reduction, and Genetics

[Associations between violence, distress, and cancer in transgender and non-transgender people.](https://meetings.asco.org/abstracts-presentations/233111)

June 3; 1:30 – 4:30PM CDT

Presenter: Ash Alpert

Location: Abstract 10566 | Poster Bd 93

*Poster Session*

Symptom Science and Palliative Care

[Factors associated with sexual function and sexual satisfaction in young women with breast cancer.](https://meetings.asco.org/abstracts-presentations/233398)

June 3; 1:30 – 4:30PM CDT

Presenter: Ana Ferrigno Guajardo

Location: Abstract 12062 | Poster Bd 191

*Poster Session*

Symptom Science and Palliative Care

[Neurofilament light chains: A biomarker for vincristine-related neuropathy.](https://meetings.asco.org/2024-asco-annual-meeting/15799?presentation=231291#231291)

June 3; 1:30 – 4:30PM CDT

Senior Author: Maryam Lustberg

Location: Hall A | Abstract 12114 | Poster Bd 243

*Poster Session*

Lung Cancer

[Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).](https://meetings.asco.org/2024-asco-annual-meeting/15775?presentation=232386#232386)

June 3; 1:30 – 4:30PM CDT

Senior Author: Roy Herbst

Location: Hall A | Abstract 8046 | Poster Bd 308

*Poster Session*

Lung Cancer

[Lymph node metastasis prediction with non-small cell lung cancer histopathology imaging.](https://meetings.asco.org/abstracts-presentations/237853)

Presenter: Victor Lee

June 3; 1:30 – 4:30PM CDT

Location: Hall A | Abstract 8063 | Poster Bd 325

*Poster Session*

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

[Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.](https://meetings.asco.org/abstracts-presentations/236960)

June 3; 1:30 – 4:30PM CDT

Presenter: Amin Nassar

Location: Hall A | Abstract 8106 | Poster Bd 368

*Poster Session*

Lung Cancer—Non-Small Cell Metastatic

[Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.](https://meetings.asco.org/abstracts-presentations/232237)

June 3; 1:30 – 4:30PM CDT

Presenter: Kelsey Matteson

Location: Hall A | Abstract 8602 | Poster Bd 466

*Clinical Science Symposium*

Making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer

[Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.](https://meetings.asco.org/abstracts-presentations/232564)

June 3; 3:12 – 3:24PM CDT

Presenter: Barbara Burtness

Location: E451 | Abstract 6009

*Education Session*

Shaping the Future of Cancer Care: Diverse Perspectives on Emerging Health Policies

[Impact of Emerging Legislation on Cancer Care—A Hospital-Based Perspective](https://meetings.asco.org/2024-asco-annual-meeting/15681?presentation=228361#228361)

June 3; 3:15 – 3:30 PM CDT

Presenter: Osama Abdelghany

Location: S102

*Oral Abstract*

Breast Cancer—Local/Regional/Adjuvant

[Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.](https://meetings.asco.org/abstracts-presentations/232431)

June 3; 5:24 – 5:36PM CDT

Presenter: Lajos Pusztai

Location: Hall B1 | Abstract 508

**Tuesday, June 4**

*Oral Abstract Session*

[Head and Neck Cancer](https://meetings.asco.org/2024-asco-annual-meeting/15843?presentation=238932#238932)

Chair: Aarti K. Bhatia

June 4; 9:45 – 12:45PM CDT

Location: S100a | Live Stream

*Oral Abstract*

Head and Neck Cancer

[A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).](https://meetings.asco.org/2024-asco-annual-meeting/15843?presentation=239189#239189)

June 4; 10:57 – 11:09AM CDT

Senior Author: Sara Pai

Location: S100a | Abstract 6004

**Publications Only**

*Publication Only*

Central Nervous System Tumors

[HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer.](https://meetings.asco.org/abstracts-presentations/237468) Senior Author: Kurt Schalper

Location: Abstract e14014

*Publication Only*

Care Delivery/Models of Care

[Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.](https://meetings.asco.org/abstracts-presentations/237156)

Senior Author: Neal Fischbach

Location: Abstract e13586

*Publication Only*

Pediatric Oncology

Modeling response to alkylating chemotherapy in a syngeneic model of MMR-deficient glioma.

article

Senior Author: Deepti Bhatt

Location: Abstract e22001

[**https://meetings.asco.org/abstracts-presentations/231055**](https://meetings.asco.org/abstracts-presentations/231055)

*Publication Only*

Breast Cancer

[Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer.](https://meetings.asco.org/abstracts-presentations/235050)

Senior Author: Maryam Lustberg

Location: Abstract #e12639

*Publication Only*

Sarcoma

[Survival trends of soft tissue sarcomas and gastrointestinal stromal tumors from 1995 to 2019: A SEER database analysis.](https://meetings.asco.org/abstracts-presentations/237942)

Senior Author: Philippos Costa

Location: Abstract #e23528

*Publication Only*

Melanoma/Skin Cancers

[Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.](https://meetings.asco.org/abstracts-presentations/236436)

Author: Daniel Lee

Location: Abstract e21522

*Publication Only*

Symptom Science and Palliative Care

[Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.](https://meetings.asco.org/abstracts-presentations/231445)

Author: Neal Fischbach

Location: Abstract e24140

*Publication Only*

Care Delivery and Quality Care

[Personalized risk assessment of new onset depression in long-term cancer survivors.](https://meetings.asco.org/abstracts-presentations/238881)

[article](https://meetings.asco.org/abstracts-presentations/238881)

Author: Melissa Taylor

Location: Abstract e13798

*Publication Only*

Medical Education and Professional Development

[A medical school curriculum to foster the physician-patient relationship through narrative medicine.](https://meetings.asco.org/abstracts-presentations/236399)

[article](https://meetings.asco.org/abstracts-presentations/236399)

Author: Johnathan Yao

Location: Abstract e21015

*Publication Only*

Care Delivery/Models of Care

[The unmet needs of women with metastatic breast cancer in Mexico: A qualitative study.](https://meetings.asco.org/abstracts-presentations/237216)

Author: Ana Ferrigno Guajardo

Location: Abstract e13547

*Publication Only*

Lung Cancer

[Real world outcomes of patients with small cell lung cancer (SCLC) presenting with brain metastasis at diagnosis in a single institution health system.](https://meetings.asco.org/abstracts-presentations/238137)

Author: Julia Joseph

Location: Abstract: e20136